Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Transition School > Medications > Flashcards

Medications Flashcards

1
Q

Adrenaline Presentation

A

1mg in 1ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Adrenaline Introduction

A

A naturally occurring sympathomimetic agent

Causes:
- Peripheral Vasoconstriction
- Stimulation of cardiac conduction system —> increased contractions
- Bronchodilaton
- Dilation of muscle blood vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Adrenaline Onset

A

IV/IO: Onset 30 seconds, half-life 5 minutes, duration 5-10 minutes

IM: Onset 60 seconds, half-life 5 minutes, duration 5-10 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Adrenaline Indications

A
  • Anaphylaxis
  • Life-threatening asthma
  • Cardiac Arrest
  • Post-ROSC
  • Severe croup
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Adrenaline Contraindications

A

Nil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Adrenaline Precautions/Notes

A
  • Ischaemic Heart Disease
  • Hypertension
  • Hypovolaemia
  • Do not walk patient pre or post IM adrenaline administration in anaphylaxis - usually min of 1 hour after 1x dose and 4 hours if >1 dose
  • If given IV into a peripheral vein, follow each dose with a sodium chloride flush
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Amiodarone Presentation

A

150mg in 3mL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Amiodarone Introduction

A

Primarily Class III antidysrhythmic agent
Prolongs action potential duration and hence refractory period of atrial, nodal and ventricular tissue
Has characteristics of all Vaughn-Williams classifications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Amiodarone Onset

A

Immediate onset
Peak <10 minutes
Duration 30-60 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Amiodarone Indications

A

Cardiac Arrest with persistent/shock resistant VF/pulseless VT, post 3rd shock

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Amiodarone Contraindications

A

No contraindications in cardiac arrest
Not compatible with Saline (if infusion dose is advocated by a specifically authorised person)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Amiodarone Precautions

A
  • Heart Failure
  • Thyroid dysfunction
  • Amiodarone is only indicated for shock resistant or recurrent VF / pulseless VT
  • MUST NOT be diluted into NaCl (e.g. if infusion doses are advised via ASMA / CSP)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Amiodarone Special Considerations

A

Bradycardia
Hypotension
Polymorphic tachycardias
Nausea
Tremor
Phlebitis
Dizziness
Paraesthesia
Headaches

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Adrenaline Special Considerations

A

Tachyarrhythmias, palpitations
Hypertension
Pupil dilation
Tremor
Anxiety

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Aspirin Presentation

A

300mg tablet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Aspirin Introduction

A
  • Analgesic
  • Antipyretic
  • Anti-inflammatory
  • Anti-platelet aggregation agent

Reduces mortality significantly in AMI by minimising platelet aggregation and thrombus formation to retard the progression of coronary artery thrombosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Aspirin Indications

A

Chest pain / discomfort of presumed cardiac origin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Aspirin Contraindications

A

Known hypersensitivity to aspirin / salicylates
Children < 16 years of age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Aspirin Precautions

A

Actively bleeding peptic ulcers
Suspected AAA
Aspirin / salicylate-sensitive asthmatics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Aspirin Special Considerations

A
  • Heart burn, nausea, GI bleeding
  • Increased bleeding time
  • Anaphylactic reaction
    (some patients, especially asthmatics) exhibit notable sensitivity to aspirin, which may provoke various hypersensitivity / allergic reactions)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Atropine Presentation

A

1.2mg in 1ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Atropine Introduction

A
  • Anticholinergic agent:
    Inhibits acetylcholine at post-ganglionic nerves at neuroeffector site —> blocks vagal stimulation —> sympathetic response —> increase pulse rate by increasing SA node firing rate and increasing conduction velocity through the AV node
  • Antidote to reverse the effects of cholinesterase inhibitors eg organophosphate poisoning
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Atropine Indications

A
  1. Symptomatic Bradycardia, haemodynamically unstable due to the bradycardia and associated with poor signs of perfusion, including:
    - Hypotension
    - Altered conscious state
    - Diaphoresis
    - Shortness of breath, and/or cyanosis
    - Syncope
  2. Organophosphate poisoning with cholinergic effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Atropine Contraindications

A

Known hypersensitivity
Patients with cardiac transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Atropine Precautions

A
  • May not be effective with 3rd degree heart block
  • Isolated Bradycardia or link to traumatic cause is not an indication for atropine. All reversible causes should be addressed prior to consideration of Atropine.
  • 12 lead ECG prior to rule out STEMI and 3rd degree
  • Bradycardia in children is usually a result of hypoxia or vagal stimulation. Look at reversible causes
  • May affect glaucoma
  • Max effective dose is 3mg for bradycardia. For organophosphate repeat doses may be required and is achieved when with an increased HR, dilated pupils and decreased secretion, do not delay transport as atropinisation might not be achievable in the pre-hospital setting.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Atropine Special Considerations

A

Tachycardia and/or palpitations
Dilated pupils and/or blurred vision
Dry mouth and/or urinary retention
Confusion, restlessness (large doses)
Hot, dry skin (large doses)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Cophenylcaine Introduction

A

Topical pump spray containing:

Lignocaine hydrochloride 50mg/ml
Phenylephrine 5mg/ml

A topical local anaesthetic and haemorrhage control agent for the relief of surface pain, nasal and oral bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Cophenylcaine Indications

A

Local pain: abrasions, small cuts and wounds
Relief of mild and moderate epistaxis
Post tonsillectomy haemorrhage
Intra-oral haemorrhage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Cophenylcaine Contraindications

A

Hypersensitivity to phenylephrine, lignocaine or other anaesthetics
Children <2yrs
Pregnancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Cophenylcaine Precautions

A

Caution with cardiovascular, hepatic and/or renal disease.
For oral use, nozzle inserted within the anterior 1/3 of mouth to avoid gag stimulation.
Each spray delivers 100 microlitres of fluid. The dose of lignocaine in each squirt is 5 mg and the dose of phenylephrine in each squirt is 0.5mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Cophenylcaine Special Considerations

A

Oral administration may cause a transient bitter taste.
Pause between subsequent doses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Droperidol Presentation

A

10mg in 2ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Droperidol Introduction

A

A neuroleptic, antipsychotic agent that acts on Alpha and Dopamine receptors, resulting in sedation

Use of a sedative agent should never be considered routine. Have a high threshold to offer or administer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Droperidol Onset

A

3-5 min IV and IM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Droperidol Indications

A
  • Disturbed and Abnormal Behaviour (RASS 1 ~ 3) if considered appropriate where risk to safety is evident and de-escalation has not been effective.
  • Dementia and frail patients where Olanzapine cannot be administered or is ineffective.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Droperidol Contraindications

A
  • Known allergy
  • Known Parkinson’s Disease
  • Where Ketamine has been administered to sedate this episode
  • Age < 6 years old
  • Post-ictal Disturbed & Abnormal Behaviour
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Droperidol Precautions

A
  • Address organic causes for behavioural presentations at all times- eg. CVA, TBI, Hypoxia, Hypoglycaemia, etc
  • Post-ROSC agitation - consult ASMA / SOC CSP
  • Dementia patients – apply caution. Use lower doses
    ‘Agitated or Excited Delirium’, ‘Acute Behavioural Disturbance’ and ‘Drug Induced Psychosis’ are some alternative terms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Droperidol Special Considerations

A
  • Extrapyramidal effects / Dyskinesia
  • Increased falls risk
  • Hypotension
  • Apply monitoring as soon as practicable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Sedation Warnings

A
  • Sedation is HIGH RISK – only after careful deliberation between officers and must not be based primarily at the request or influence of other agencies on scene (e.g. Police etc.)
  • Positive RASS score does not automatically = need to sedate
  • Age <16 years old – prior ASMA consult wherever practicable
  • ETOH / Intoxication – apply caution
  • Repeat & Maintenance doses – have low threshold to consult ASMA for repeat or maintenance doses
  • SpO2 and EtCO2 monitoring whenever level of consciousness drops (~RASS -2 or below)
  • DO NOT transport in supine position (increases risk of laryngospasm from secretions) – transport in lateral position
  • Monitor airway and breathing effort closely for signs of impairment
  • Restraint – Prone and/or handcuffed to rear carries excessive risk and MUST NOT occur. Physical restraint in any position that amplifies the risk of positional asphyxia, must be closely observed for signs of air hunger and hypoxia
  • RASS scores must be agreed and documented
  • Estimated weight must be agreed before administration and documented
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Fentanyl Presentation

A

IN: 450mcg in 1.5ml
IV/IO: 100mcg in 2ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Fentanyl Introduction

A

A short acting synthetic narcotic analgesic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Fentanyl Indications

A

Moderate to severe pain.
Acute Coronary Syndromes where GTN has been ineffective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Fentanyl Contraindications

A

Hypersensitivity
Child <1 year of age (IV / IO only)
Occluded nasal passages or epistaxis (IN only)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Fentanyl Precautions

A
  • Elderly patients
  • Respiratory depression: especially those at risk e.g. patients with severe COPD
  • Patients currently on MAO inhibitors or MAO inhibitor use within previous 14 days
  • Caution in larger doses of women in active labour
  • Use of IV Ketamine as analgesic prior to minimum dose of IV Fentanyl requires ASMA authorisation:
    Paediatric: 100 microg
    Adult < 70 years old: 200 microg
    Adult > 70 (or frail): 100 microg
  • Administer slowly
  • Cease administration prior to calculated dose if desired effect is obtained.
  • Patients under extended care (e.g. ‘ramped’ patients) who have already been administered pain relief should have careful consideration with regards to the dosages of fentanyl administered, titrating only to effect.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Fentanyl Special Considerations

A
  • Adopt a low threshold to engage with the ED team if pain remains difficult to control
  • Drowsiness
  • Nausea/vomiting
  • Respiratory depression; (monitor pulse oximetry)
  • Cardiovascular effects:
    Bradycardia
    Hypotension (rare)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Glucagon Presentation

A

1mg in 1ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Glucagon Introduction

A

A hyperglycaemic agent that converts stored liver glycogen to glucose to increase blood glucose concentration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Glucagon Onset

A

4-7 minutes, duration 10-30 minutes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Glucagon Indications

A

For demonstrated hypoglycaemia where oral glucose cannot be administered and IV access cannot be obtained in a safe and timely manner.

          - Altered conscious state in a known diabetic or of otherwise unknown cause where blood glucose level is below 4mmol/L.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Glucagon Contraindications

A

Hypersensitivity
Known pheochromocytoma, insulinoma & glucagonma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Glucagon Precautions

A
  • Only effective if sufficient liver glycogen is present (eg: it does not work on alcohol or anorexia induced hypoglycaemia).
  • Even if fully recovered, encourage transport for follow up and review.
  • Give complex carbohydrates orally when patient has responded to prevent recurrence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Glucagon Special Considerations

A

Nausea/vomiting
Gastric pain
Transient rise of blood pressure for patients taking beta blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Glucose (IV) Presentation

A

500ml bag 10% glucose
10g per 100ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Glucose (IV) Introduction

A
  • A hypertonic crystalloid solution that provides a readily available source of energy (glucose)
  • Contains 100 mg glucose anhydrous/ml
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Glucose (IV) Onset

A

1 minute

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Glucose (IV) Indications

A

Demonstrated hypoglycaemia where oral glucose administration is inappropriate in:

 - Altered conscious state in known diabetic or of otherwise unknown cause where blood glucose level is below 4 mmol/L.
 - Cardiac arrest, only if hypoglycaemia is suspected as a contributory cause of the arrest, not an early indication.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Glucose (IV) Contraindications

A

No IV access

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Glucose (IV) Precautions

A
  • Large gauge cannula into a large vein, with patency with free flowing bolus (>20 mL) of 0.9% normal saline, before administering glucose 10% using a 20 mL syringe via the injection port, titrated to effect.
  • Administration via an IO should utilise a 20 mL syringe and a three way tap.
  • High concentration of IV glucose may aggravate dehydration due to its hypertonicity whereby it draws water from the cells.
  • IV glucose is corrosive and IV patency must be ensured before administration.
  • Careful titration of glucose in head injured patients is vital as glucose leaking into CNS tissue will aggravate the injury, resulting in cerebral oedema.
  • Monitor blood glucose level carefully; beware of drop in level again after the patient has recovered.
  • Even if fully recovered, encourage transport
  • IO administration is only as a last resort after all other avenues have been exhausted and the patient needs lifesaving glucose.
  • Do not wait on scene for glucose to take effect.
  • Note that repeat doses of Glucose 10% (Intravenous) may be needed achieve normoglycaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Glucose (IV) Special Considerations

A

Hyperglycaemia
Diuresis
Tissue necrosis
Thrombophlebitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Glucose Oral Gel Presentation

A

15g tube

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Glucose Oral Gel Introduction

A

Rapidly absorbed from oral/buccal mucosa to increase blood glucose concentration
Contains 15g glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Glucose Oral Gel Onset

A

2-5 minutes; duration 12-25 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Glucose Oral Gel Indications

A

Demonstrated hypoglycaemia in:

  • Altered conscious state in a known diabetic.
  • Altered conscious state of unknown medical cause, where blood glucose level is below 4 mmol/L.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Glucose Oral Gel Contraindications

A

Nil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Glucose Oral Gel Precautions

A
  • Airway patent and in lateral position if unconscious.
  • Always consider airway when administering gel.
  • Even if fully recovered, encourage to be transported to a medical facility to ensure effective follow up and review.
  • Will liquefy over 30°C, however it is still useable.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Glucose Oral Gel Special Considerations

A

Airway Obstruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

GTN Presentation

A

400mcg per spray

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

GTN Introduction

A

Nitrates cause the relaxation of vascular smooth muscle resulting in:

  • Vasodilation
  • Peripheral pooling and reduced venous return
  • Reduced left ventricular end diastolic pressure (preload)
  • Reduced systemic vascular resistance (afterload)
  • Reduced myocardial energy and oxygen requirements
  • Relaxes spasm of coronary arteries
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

GTN Indications

A
  • Chest pain/discomfort of presumed cardiac origin not relieved by rest and reassurance with systolic BP > 90 mmHg.
  • Acute Cardiac Pulmonary Oedema with systolic BP >90 mmHg.
  • Autonomic Dysreflexia with systolic BP > 160 mmHg.
70
Q

GTN Contraindications

A
  • Hypersensitivity
  • Hypotension < 90 mmHg
  • Recent use of medications used for erectile dysfunction:
    Sildenafil (Viagra®) or Vardenafil (Levitra®) or Avanafil (Spedra®) use in the previous 24 hours
    Tadalafil (Cialis®) use in the previous 3 days
71
Q

GTN Precautions

A
  • Nitrates = early intervention, do not delay
  • Administer in seated or semi-recumbent position
  • Do not shake GTN bottle prior to administration
  • Assess BP before every dose
  • Severe hypotension is an uncommon side effect
  • Intoxication (effect are enhanced)
  • Phosphodiesterase 5 inhibitor medication administration in previous 4 days
72
Q

GTN Special Considerations

A

Hypotension (rare)
Tachycardia
Flushing
Headache
Dizziness

  • when GTN infusion used for ACPO, hypotension side effects amplified
73
Q

Heparin Sodium Presentation

A

5000IU in 5mL

74
Q

Heparin Introduction

A

A naturally occurring anticoagulant which inhibits the clotting of blood by increasing the rate at which antithrombin III neutralises thrombin and activated factor X (Xa)

75
Q

Heparin Onset

A

IV: Immediate

76
Q

Heparin Indications

A

Patients with STEMI going directly to Cardiac Catheterisation Laboratory as per receiving hospital 12-lead ECG interpretation

77
Q

Heparin Contraindications

A
  • Hypersensitivity to Heparin
  • Active bleeding (excluding menses) or disease states with an increased risk of bleeding (e.g. haemophilia)
78
Q

Heparin Precautions

A

Haemorrhagic risks in case of possible trauma

79
Q

Heparin Special Considerations

A

Haemorrhage
Hyperkalaemia
Thrombocytopenia

80
Q

Intravenous Crystalloid Solutions (Normal Saline) Presentation

A

0.9% in 250ml or 1000ml
10ml flush

81
Q

Normal Saline Introduction

A

A sterile isotonic crystalloid solution

82
Q

Normal Saline Indications

A

Fluid replacement (volume expansion) for the treatment of shock, fluid loss, and cardiac arrest.

83
Q

Normal Saline Contraindications

A

Severe pulmonary oedema

84
Q

Normal Saline Precautions

A

Adult patients with penetrating trauma, ectopic pregnancy or aortic aneurysm with hypotension and signs of impaired organ perfusion may benefit from permissive hypotension (systolic blood pressure of 70mmHg)

85
Q

Normal Saline Special Considerations

A

Hypervolemia

86
Q

Ipratropium Bromide Presentation

A

250mcg in 1ml
20mcg per puff MDI

87
Q

Ipratropium Bromide Introduction

A
  • An anticholinergic bronchodilator. It inhibits the vagal reflexes that mediate bronchospasm
  • Combined with a nebulised short-acting beta-2 agonist (e.g. salbutamol), ipratropium bromide produces significantly greater bronchodilation than a short-acting beta-2 agonist alone
88
Q

Ipratropium Bromide Indications

A

Severe bronchospasm:

  • Adult: Severe to life-threatening asthma or COPD
  • Paediatric: Severe to life-threatening asthma
89
Q

Ipratropium Bromide Contraindications

A

Hypersensitivity

90
Q

Ipratropium Bromide Precautions

A
  • Glaucoma
  • Avoid contact with eyes
91
Q

Ipratropium Bromide Special Considerations

A

Headache
Nausea, dizziness
Dry mouth, throat irritation
Taste disturbance
Skin rash

92
Q

Ketamine Presentation

A

200mg in 2ml

93
Q

Ketamine Introduction

A

Rapid acting dissociative anaesthetic
Use of a sedative agent should never be considered routine. Have a high threshold to offer or administer

94
Q

Ketamine Onset

A

IM: 5-10 minutes
IV: 1 minute

95
Q

Ketamine Indications

A
  • IV: Second line agent for severe pain of traumatic origin post IV Fentanyl administration. ASMA consult needed if IV Fentanyl minimum dose (age dependent as per CPG) has not been given prior to IV Ketamine administration
  • IM: First line agent for severe pain of traumatic origin should other means of administering pain medication not be available
  • Combative Traumatic Brain Injury
  • (RASS 4) First line agent for severely disturbed or abnormal behaviour where there is an immediate risk to safety and rapid tranquilisation is required and no other sedative medications have already been administered to this patient
96
Q

Ketamine Contraindications

A
  • Hypersensitivity
  • Active cardiovascular disease including cardiac chest pain, heart failure, severe or poorly controlled hypertension
  • Patients with delayed transfer of care (i.e. ‘ramped’)
  • Disturbed and abnormal behaviour that are clearly not RASS 4 or where other sedative agents have already been administered (ASMA authority required)
  • Rapid Tranquilsation ONLY: Age < 16 years old
  • Age < 1 years old
97
Q

Ketamine Precautions

A
  • Stable psychiatric disorders such as Schizophrenia
  • Hyperthyroidism or receiving thyroid replacement due to increased risk of hypertension and tachycardia
  • Analgesia – IV Fentanyl minimum dose (age dependant as per CPG) should be given prior to IV Ketamine administration
  • Analgesia for Non traumatic pain (IM / IV / IO) in opioid-dependent patients – consider SOC CSP consult
  • Sedation warnings
98
Q

Ketamine Special Considerations

A

Blood pressure and pulse frequently elevated
Random purposeless movements, muscle twitching and rash are common
Hypersalivation
Emergence reactions (10%)
Transient laryngospasm
Transient apnoea or respiratory depression

99
Q

Lignocaine Presentation

A

20mg in 2ml OR 50mg in 5ml

100
Q

Lignocaine Onset

A

1-2 minutes

101
Q

Lignocaine Introduction

A

Reversibly interrupt impulse conduction in peripheral nerves and stabilise excitable cell membranes by blocking Sodium Channels

102
Q

Lignocaine Indications

A

Local anaesthesia for:
- IV cannulation
- IO infusion
- Suturing
- Finger thoracostomy in the conscious patient

103
Q

Lignocaine Contraindications

A

Hypersensitivity

104
Q

Lignocaine Precautions

A

Adverse drug reactions are rare when lignocaine is used as a local anaesthetic and is administered correctly.

105
Q

Lignocaine Special Considerations

A
  • Tinnitus, dizziness, anxiety, confusion, perioral numbness
  • Cardiovascular effects: Bradycardia, hypotension, dysrhythmias
  • CNS effects
  • Respiratory depression
106
Q

Methoxyflurane Presentation

A

3mL ampoule

107
Q

Methoxyflurane Introduction

A

A halogenated ether that produces powerful modification of the awareness of pain with an associated light headed sensation.

108
Q

Methoxyflurane Onset

A

6-8 breaths, 1-2 minutes, peak 2-4 minutes

109
Q

Methoxyflurane Indications

A

Pain

110
Q

Methoxyflurane Contraindications

A

Patients who are unable to understand or co-operate.
Patients with severe renal impairment.
Patients with head injury and altered consciousness that prevents co-operation with its use.
Hypersensitivity e.g. malignant hyperthermia

111
Q

Methoxyflurane Precautions

A
  • Use charcoal filter
  • Use extractor fan during transit
  • Instruct the patient to breathe in through their mouth and out through their mouth via the inhaler. For maximum effect cover the air dilutor hole.
  • Initial breath is strong and may cause the patient to cough, so advise to take gently
  • Watch for drowsiness
  • If oxygen is required deliver separately
  • Place in a sealed plastic bag when not in use
112
Q

Methoxyflurane Special Considerations

A

Lightheaded
Dizziness
Drowsy
Nausea
Malignant hyperthermia

113
Q

Midazolam Presentation

A

15mg in 3ml

114
Q

Midazolam Introduction

A

A water-soluble benzodiazepine that has anxiolytic, sedative and anticonvulsive characteristics. This is due to its bonding with receptors in the CNS; its action to increase the inhibitory effect of the g-aminobutyric acid (GABA) neurotransmitter on the GABA receptors and subsequent membrane threshold.

  • Midazolam is lipid-soluble in physiological pH and it reaches the CNS quickly.
  • Use of a sedative agent should never be considered routine. Have a high threshold to offer or administer.
115
Q

Midazolam Indications

A
  • Prolonged seizure activity - generalised seizure lasting ≥ 5 minutes OR recurrent / status seizure activity as per CPG
  • Focal seizure activity which is prolonged (≥ 5 minutes) and is associated with a GCS ≤ 12 as per CPG
  • Second-line IV agent for maintenance of sedation after Droperidol administration for Disturbed and/or Abnormal Behaviour
116
Q

Midazolam Contraindications

A

Hypersensitivity
Use of Midazolam for sedation after Ketamine requires ASMA authority

117
Q

Midazolam Precautions

A
  • Early monitoring as soon as practicable is required when administering midazolam; including SpO2, respiratory rate, pulse and blood pressure
  • SpO2 and EtCO2 monitoring must be applied whenever level of consciousness drops consistent with the Sedative Warnings section.
  • Psychostimulants, in toxic levels can produce severe agitation and psychotic behaviour
  • Paediatric patients:
    Intramuscular administrations should always be prepared in a 1mL IM syringe
    Have a low threshold to consult with ASMA when repeat or maintenance doses are required for sedation
118
Q

Midazolam Special Considerations

A

Respiratory depression
Hypotension
Anterograde and retrograde amnesia
Myasthenia Gravis

119
Q

Naloxone Presentation

A

0.4mg in 1ml

120
Q

Naloxone Introduction

A

A pure opioid antagonist; exerts effect by competitive inhibition at the opioid receptor sites.
Prevents or reverses the effects of opioids, including: respiratory depression sedation and hypotension.
In the absence of opioids, it exhibits essentially no pharmacological activity.

121
Q

Naloxone Indications

A

Reversal of respiratory depression in a suspected narcotic overdose

122
Q

Naloxone Contraindications

A

Hypersensitivity

123
Q

Naloxone Precautions

A
  • Polypharmacy overdose.
  • Half-life of naloxone is < 1 hour; repeat doses may be required to maintain effect with longer acting opioids and those with active metabolites (e.g. methadone, diphenoxylate, codeine). Observe patients who respond to naloxone for 2-3 hours after administration for signs of re-narcotisation.
  • Response to Naloxone is rapid; reconsider diagnosis if there is a failure to respond to 2 mg Naloxone.
  • Patients may be aggressive post Naloxone and administration due to hypoxia. Scene safety and personal safety are paramount.
124
Q

Naloxone Special Considerations

A

Withdrawal symptoms such as:

Aggression
Agitation
Nausea/vomiting
Dilated pupils and lacrimation

THN - max dose is 3.6mg, attempt to convince to transport to hospital, if not leave them with THN, document if given, only give to SJA patients

125
Q

Olanzapine Presentation

A

5mg tablet

126
Q

Olanzapine Introduction

A

A second generation antipsychotic agent that acts on multiple receptors (incl. serotonin and dopamine receptors), resulting in sedation

Use of a sedative agent should never be considered routine. Have a high threshold to offer or administer.

127
Q

Olanzapine Onset

A

~10 minutes

128
Q

Olanzapine Indications

A
  • Disturbed and Abnormal Behaviour (RASS 1 ~ 3) if considered appropriate where risk to safety is evident and de-escalation has not been effective
  • Patient is able to tolerate or self-administer an oral wafer
  • Preferred first line sedation agent in frail patients and those with Dementia
129
Q

Olanzapine Contraindications

A

Known Allergy
Known Parkinsons Disease
Age < 6 years old

130
Q

Olanzapine Precautions

A
  • Address organic causes for behavioural presentations at all times- eg. CVA, TBI, Hypoxia, Hypoglycaemia, etc
  • Dementia patients – apply caution. Use lower doses
  • Oral dispersible tablet may be dissolved in water (may slightly delay onset of action but still preferable in non-emergent cases)
  • ‘Agitated or Excited Delirium’, ‘Acute Behavioural Disturbance’ and ‘Drug Induced Psychosis’ are some alternative terms that may be used by other agencies
131
Q

Olanzapine Special Considerations

A

Extrapyramidal effects / Dyskinesia
Increased falls risk
Hypotension – Apply monitoring as soon as practicable

132
Q

Ondansetron Presentation

A

4mg in 2ml
4mg wafer

133
Q

Ondanestron Introduction

A
  • Anti-nauseant and anti-emetic
  • Selective 5-HT3 receptor antagonist blocking serotonin centrally in the chemoreceptor trigger zone and peripherally on Vagus nerve terminals.
134
Q

Ondansetron Onset

A

Up to 30 minutes

135
Q

Ondansetron Indications

A

Moderate to severe nausea
Active vomiting
Prophylaxis for eye and spinal injuries

136
Q

Ondansetron Contraindications

A

Paediatrics <2 years old
Hypersensitivity

137
Q

Ondansetron Precautions

A
  • Oral wafer is the preferred method of administration for ALL patients unless actively vomiting.
  • Administer IV Ondansetron slowly over 2 minutes (neat or diluted) to prevent blurred vision and dizziness.
138
Q

Ondansetron Special Considerations

A

Headache
Malaise/fatigue
Drowsiness
Dizziness
Rash/allergic reaction

139
Q

Oxygen Introduction

A

Oxygen is a treatment for hypoxaemia and has not been shown to have any effect on breathlessness in non-hypoxaemic patients.

140
Q

Oxygen Indications

A

Adult:
- Oxygen should be titrated to achieve oxygen saturations of between 94 – 98%, (or 88 – 92% for COPD patients). These are achieved through the use of different flow rates and oxygen masks.

Paediatric:
- All paediatric patients with significant illness or injury should receive oxygen. Newborn resuscitation should ideally be commenced with room air for the first couple of breaths.

141
Q

Oxygen Contraindications

A

Explosive or flammable environments
Normoxia

142
Q

Oxygen Precautions

A
  • If the target saturations cannot be maintained with the nasal cannula or medium concentration mask then change to a non-rebreather oxygen mask.
  • Oxygen increases the toxicity in paraquat poisoning, target saturations of 88–92%.
  • Remember that some conditions can affect SpO2 readings e.g. carbon monoxide poisoning and cold digits
143
Q

Oxygen Special Considerations

A
  • Patients with acute episodes of COPD are at risk of developing carbon dioxide retention if they are given excessive supplemental oxygen. This can cause acidosis and subsequent organ dysfunction.
  • High oxygen concentrations can lead to increased production of reactive free radicals resulting in cellular damage. This may be responsible for the detrimental effects observed with the use of high flow oxygen in myocardial infarction and stroke.
144
Q

Paracetamol Presentation

A

500mg tablet

145
Q

Paracetamol Introduction

A

A p-aminophenol derivative that exhibits analgesic and antipyretic activity.

146
Q

Paracetamol Onset

A

≥ 30 minutes

147
Q

Paracetamol Indications

A

Mild to moderate pain
- For example, headache, sprain/strain, toothache, etc.
- As a component of a multimodal analgesic regime.

148
Q

Paracetamol Contraindications

A
  • Known hypersensitivity to Paracetamol.
  • Do not give if patient has had Paracetamol in the preceding 4 hours.
  • Cannot exceed the maximum allowed single dose or exceed the maximum allowed paracetamol daily dose (24hrs).
149
Q

Paracetamol Precautions

A
  • There is no evidence that fever itself worsens the course of an illness. The primary goal should be to improve overall comfort
  • SJA do not support the use of paracetamol in infants < 6 months.
  • 100mg/mL suspension bottle (20 mL) Paracetamol suspension bottle is single patient use only.
    Only used enteral syringe/dropper with suspension
150
Q

Paracetamol Special Considerations

A

Nil known at therapeutic doses

151
Q

Prednisolone Presentation

A

25mg in 5ml

152
Q

Prednisolone Introduction

A

Redipred Oral 30ml elixir for oral administration
A steroid that prevents the release of inflammatory mediators

153
Q

Prednisolone Onset

A

Peak effect 1 hour

154
Q

Prednisolone Indications

A
  • Mild / Moderate croup
  • Severe croup after nebulised Adrenaline administration
155
Q

Prednisolone Contraindications

A

Known hypersensitivity to corticosteroids
Live virus immunisation within last 48 hours (e.g. MMR, Chicken Pox, Yellow Fever)

156
Q

Prednisolone Precautions

A
  • 30ml Bottle is single patient use only
  • Children who are on immunosuppressant drugs are more susceptible to infections than healthy children, e.g.: Chicken pox and measles
  • Impaired immune responsiveness
157
Q

Prednisolone Special Considerations

A
  • Side effects occur following prolonged use and are of little consequence in an emergency setting
  • Vomiting
158
Q

Salbutamol Presentation

A

5mg in 2.5ml
100mcg per puff

159
Q

Salbutamol Introduction

A

Short acting Beta 2 agonist that causes relaxation of bronchial smooth muscle (bronchodilation).

160
Q

Salbutamol Onset

A

2-5 minutes, maximum by 10 minutes.

161
Q

Salbutamol Indications

A

Bronchospasm and respiratory distress associated with wheeze:

  • Acute Bronchial Asthma
  • Bronchitis
  • Smoke inhalation
  • Severe allergic / anaphylactic reactions
  • Acute Pulmonary Oedema of non-cardiac origin
  • Salt Water Aspiration Syndrome (SCUBA divers)
  • Chronic Obstructive Pulmonary Disease (COPD)
162
Q

Salbutamol Contraindications

A

Known hypersensitivity to salbutamol
Cardiogenic pulmonary oedema
Age <12 months

163
Q

Salbutamol Precautions

A
  • A spacer / MDI is the preferred route for influenza like illness.
  • MDI and spacer is equally as effective as nebulisation, in all asthma situations, where patient is still able to adequately inhale.
  • Use of a nebuliser is recommended where the patient loses this ability.
  • If hypoxic, nebulise salbutamol in preference to MDI, to address both hypoxia and bronchospasm. The nebulised route also makes it possible to administer Ipratropium Bromide simultaneously.
164
Q

Salbutamol Special Considerations

A

Muscle tremor
Tachycardia, palpitations
Headache

165
Q

Tranexamic Acid Presentation

A

1mg in 10ml

166
Q

Tranexamic Acid Introduction

A
  • Antifibrinolytic
  • A synthetic derivative of the amino acid lysine that inhibits fibrinolysis (clot breakdown) by blocking the lysine binding site on plasminogen, competitively inhibiting the activation of plasminogen to plasmin.
  • Hepatic metabolism with renal excretion.
167
Q

Tranexamic Acid Onset

A

Within minutes
Duration 17 hours, half-life 3 hours

168
Q

Tranexamic Acid Indications

A
  • Significant trauma (< 3 hours) with signs of hypovolaemia or
  • Significant active haemorrhage that requires the use of :
    • Tourniquet/s
    • Haemostatic/pressure dressing/s
  • Suspected head injury (< 3hours) with GCS motor score of 4 (withdrawing from pain) or below
  • Severe Primary or Secondary Post-Partum Haemorrhage (> 1000 mL) or PPH with signs of hypovolaemia (birth/bleed occurred < 3hrs)
  • Significant post-tonsillectomy haemorrhage
169
Q

Tranexamic Acid Contraindications

A
  • Known hypersensitivity to Tranexamic Acid.
  • Injury time more than 3 hours (associated with increase in mortality).
170
Q

Tranexamic Acid Precautions

A
  • TXA administration in the traumatic patient in the metropolitan area should ordinarily prompt transport to a major trauma centre
  • Rapid administration may lead to hypotension and dizziness.
  • No medications or blood products (except 0.9% Sodium Chloride Solution) should be added or co-administered through the same giving set.
  • Give as early as possible post event. Survival benefit is reduced by 10% for every fifteen minute delay with no benefit seen after 3 hours
  • Address critical interventions (airway management, control of major haemorrhage etc.) before administration of tranexamic acid.
  • Tranexamic acid administration should not delay transfer, noting it may be administered en route.
  • Slow IV push is the first line management option. TXA can be given via an infusion, however, familiarity in using infusions and availability of an appropriate label to identify the infusion should dictate if this option is utilised.
  • Safety during pregnancy has not been demonstrated, but the balance of risk is such that it should be administered if the indications are met in life threatening circumstances
171
Q

Tranexamic Acid Special Considerations

A

Hypotension (fast infusion rate)
Headache
Dizziness
Convulsions (lowers seizure threshold)
Nausea and/or vomiting
Diarrhoea

Transition School (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions